"
今天是:

梅虎

姓名:梅虎

性 别: 男

出生年月: 1972年10月

籍 贯:安徽芜湖

職稱職務:博士、教授、碩士生導師。

社會兼職:美國ACS會員、重慶市化學學會和生物醫學工程學會會員

通信地址:重庆市沙坪坝区沙正街174号生物工程学院 邮政编码:400044

郵箱:meihu@cqu.edu.cn

研究領域:藥物設計與藥物基因組學

招收碩士研究生專業&研究方向:1.藥學2.生物學

個人簡介

:主要从事药物设计、药物基因组学、生物信息学等领域研究。先后在《PNAS》,《Scientific Reports》,《Toxicological Sciences》,《J Chem Inf Model》,《European Journal of Medicinal Chemistry》等国际期刊上发表发表SCI收录论文60余篇,單篇最高引用90次,累計引用310余次。申請發明專利5項,獲權2项。先后主持国家高技术发展研究计划(“863”计划)、国家自然科学基金等多项省部级以上科研項目;研究成果“肽定量构效关系研究与应用”获教育部自然科学奖二等奖;曾获重庆大学“优秀青年教师”和“学生科技园丁”等荣誉称号。指导本科生参加美国数学建模竞赛获二等奖和三等奖各一项;指导研究生获得重庆市优秀博士学位论文1人,重庆市优秀硕士学位论文1人,重庆大学优秀毕业研究生3人。现为《Journal of Medicinal Chemistry》,《Bioorganic & Medicinal Chemistry Letters》,《SCIENCE IN CHINA》,《CHINESE JOURNAL OF STRUCTURAL CHEMISTRY》等杂志审稿人。

近年來,主要進行基于結構的合理藥物設計、遺傳異質性藥物毒副作用機理與個性化醫療等相關研究。歡迎藥學、生物學、化學等相關專業學生報考本學科方向研究生。

代表性論文目錄(2010~):

1. Zhang ZH, Chen S, Mei H, Xuan JK, Guo XQ, Couch L, Dobrovolsky VN, Guo L, Mei N. 2015. Ginkgo biloba leaf extract induces DNA damage by inhibiting topoisomerase II activity in human hepatic cells.Scientific Reports5

2. Sun JY, Mei H. 2015. QSAR and molecular mechanism analysis of N-substituted oseltamivir derivatives as potent avian influenza H5N1 neuraminidase inhibitors.Chemometrics and Intelligent Laboratory Systems146: 485-93

3. Pan XC, Chao L, Qu SJ, Huang SH, Yang L, Mei H. 2015. An improved large-scale prediction model of CYP1A2 inhibitors by using combined fragment descriptors.Rsc Advances5: 84232-7

4. Liu T, Pan X, Chao L, Tan W, Qu S, Yang L, Wang B, Mei H. 2014. Subangstrom accuracy in pHLA-I modeling by Rosetta FlexPepDock refinement protocol.J Chem Inf Model54: 2233-42

5. Xie JG, Xu ZL, Zhou SB, Pan XC, Cai SX, Yang L, Mei H. 2013. The VHSE-Based Prediction of Proteasomal Cleavage Sites.Plos One8

6. Tan W, Mei H, Chao L, Liu TF, Pan XC, Shu M, Yang L. 2013. Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors.Journal of Computer-Aided Molecular Design27: 1067-73

7. Tan QY, Wu JY, Li Y, Mei H, Zhao CJ, Zhang JQ. 2013. A supermolecular curcumin for enhanced antiproliferative and proapoptotic activities: molecular characteristics, computer modeling and in vivo pharmacokinetics.Nanotechnology24

8. Tan QY, Li Y, Wu JY, Mei H, Zhao CJ, Zhang JQ. 2012. An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity.International Journal of Nanomedicine7: 5385-93

9. Sun J, Mei H. 2012. Docking and 3D-QSAR investigations of pyrrolidine derivatives as potent neuraminidase inhibitors.Chemical Biology & Drug Design79: 863-8

10. Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira CAF, Yang L, Mei H, Shi L, Shabanowitz J, English AM, Wriston A, Lucas A, Phillips E, Mallal S, Grey HM, Sette A, Hunt DF, Buus S, Peters B. 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.Proceedings of the National Academy of Sciences of the United States of America109: 9959-64

11. Li Y, Mei H, Wu Q, Zhang S, Fang J-L, Shi L, Guo L. 2011. Methysticin and 7,8-Dihydromethysticin are Two Major Kavalactones in Kava Extract to Induce CYP1A1.Toxicological Sciences124: 388-99

12. Sun JY, Cai SX, Yan N, Mei H. 2010. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.European Journal of Medicinal Chemistry45: 1008-14

13. Sun JY, Cai SX, Mei H, Li JA, Yan N, Wang Q, Lin ZH, Huo DQ. 2010. Molecular Docking and QSAR Studies on Substituted Acyl(thio)urea and Thiadiazolo [2,3-alpha] Pyrimidine Derivatives as Potent Inhibitors of Influenza Virus Neuraminidase.Chemical Biology & Drug Design76: 245-54